Blockade of CCL5 previously described as mechanism
Post# of 155128
(Total Views: 664)
Posted On: 01/24/2021 2:49:59 PM
Blockade of CCL5 previously described as mechanism against rheumatoid arthritis, but not osteoarthritis.
However, blockade of CCL3 seems do the trick.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199535/
Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis
In conjunction with rheumatoid diseases, a huge market.
https://www.ajmc.com/view/a235_09sep_bitton_s230tos235
The Economic Burden of Osteoarthritis
October 7, 2009
Ryan Bitton, PharmD, MBA
However, blockade of CCL3 seems do the trick.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199535/
Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis
Quote:
Macrophage inflammatory protein 1-alpha (CCL3) is a chemokine that regulates macrophage trafficking to the inflamed joint. The agonistic effect of CCL3 on osteolytic lesions in patients with multiple myeloma is recognized; however, its role in skeletal damage during inflammatory arthritis has not been established. The aim of the study was to explore the role of osteoclast-associated CCL3 upon bone resorption, and to test its pharmacological blockade for protecting against bone pathology during inflammatory arthritis.
Quote:
Inhibition of osteoclast-associated CCL3 reduced osteoclast formation and function whilst attenuating arthritis-associated bone loss and controlling development of erosion in murine joints, thus uncoupling bone damage from inflammation. Our findings may help future innovations for the diagnosis and treatment of inflammatory arthritis.
In conjunction with rheumatoid diseases, a huge market.
https://www.ajmc.com/view/a235_09sep_bitton_s230tos235
The Economic Burden of Osteoarthritis
October 7, 2009
Ryan Bitton, PharmD, MBA
Quote:
.A continued upward trend is reflected in data from the United States in which, in 1997, the total medical expenditures for arthritis and other rheumatic conditions were $233.5 billion.8
By 2003, these costs had increased to $321.8 billion after factoring in inflation. A substantial part of these costs are specific to OA. One estimate, by Leigh et al, put the total annual costs of OA at $89.1 billion.11
They further estimated that between $3.4 billion and $13.2 billion of that expenditure was due solely to job-related OA, making job-related OA more costly than asthma and pulmonary diseases, and also more than renal and neurologic diseases combined.11
(6)
(0)